Conversations at the crossroads of science and capital.
Welcome to Clinical Capital Conversations, a podcast and editorial platform hosted by Dr. Peter M. Kovacs, a clinical research pioneer turned global investor.
At the intersection of cutting-edge science and strategic investment, we explore what it really takes to turn medical innovation into scalable impact.
Each episode features unfiltered conversations with:
Clinical research leaders are redefining how trials are run
Biotech and medtech founders building from scratch
Venture capitalists are funding the next generation of health innovation
Policymakers, regulators, and thought leaders shaping the future of medicine
Peter brings his first-hand experience, from founding one of the Worlds most agile clinical trial networks to investing in disruptive health tech startups across Asia and Europe.
This is not another hype podcast. It’s a behind-the-scenes look at how decisions are made, systems are built, and real therapies reach real patients.
Whether you’re a startup founder, scientist, investor, or healthcare strategist, CCC is your front-row seat to the people and ideas moving life sciences forward.
Join Clinical Capital Conversations and be part of the dialogue at the crossroads of science and capital. Get insights, unfiltered stories, and updates on how medical innovation turns into real-world impact, straight to your inbox.
The Real Risk Is Execution: What Investors Miss When They Fund Science Without Systems
Dr. Peter M. Kovacs speaks with Roswitha Verwer and Karoly Szanto on how YONE hit a 12-month roadmap in 6 months, why execution is the clinical moat, and what femtech fundraising still gets wrong for founders and investors.
The Co-Investor Question That Determines Everything in Biotech and Medtech
In this episode, Peter M. Kovacs, Károly Szántó, and Thijmen Meijer break down the co-investor question that drives biotech and medtech outcomes: alignment, skin in the game, and execution focused capital.
Europe Has the Science. Asia Has the Capital. The Missing Layer Is Execution
Europe has the science and Asia has the capital. In conversation with Károly Szántó and Thijmen Meijer, we break down the missing layer: execution. Learn how to build fundable teams, define milestones, and de-risk biotech and medtech commercialization.
The Operating System Behind Breakthroughs: Why Venture Studios, Focus, and Execution Decide Outcomes in Healthcare
A candid conversation with Károly Szántó on venture studios, calculated risk, founder focus, and why university spinouts need market partnership. Practical insights for investors and operators building scalable healthcare ventures.
Age Management Is Not HR. It Is an Execution Discipline Investors Cannot Ignore
Age Management is a data-driven approach to workforce resilience and execution risk. Dr.Peter M Kovacs outlines why investors and operators must rethink human capital to protect long-duration biotech and healthcare returns.
Seeing Through the Noise: The Investor Mindset That Survives Biotech Cycles
A strategic deep dive into the investor mindset required to navigate biotech cycles. Learn how disciplined skepticism, structured diligence, and operational insight protect investors from overhyped science and execution failures.
AI Memory Therapy With Real Clinical Impact: How Kompanion Care Turns Personal Loss Into Scalable Dementia Innovation
AI memory therapy is reshaping dementia care. In this episode, Peter M. Kovacs talks with Kompanion Care founder Peter Markus about clinically validated digital therapy, reimbursement pathways, and the future of early cognitive monitoring.
Inside Europe’s AI Hospitals: How Olomouc Built a Clinical Innovation Engine
A deep dive into how University Hospital Olomouc built one of Europe’s most advanced AI hospital systems. Peter M. Kovacs, Pavlina Walter, and innovation lead Antonín Hlavinka explore clinical impact, operational efficiency, and the future of agent-driven care.
InTouch with Humanity: How AI Is Redefining Care and Connection
Dr. Peter M. Kovacs, Pavlina Walter, and Vassili Le Moigne explore how AI voice technology is transforming elder care, combating loneliness, and scaling compassion with trust and privacy at its core.
The Future of Biologics: How Strategic CROs are Powering the Next Generation of Clinical Research
Biologics are redefining clinical research. Dr. Peter M. Kovacs, Pavlina Walter, and Jiri Raska discuss how strategic CROs are driving biotech scalability, from analytics to clinical trials, and why integration is the new competitive edge.
Leading with Value: Lessons in Leadership, Legacy, and Resilience
Peter M. Kovacs, Pavlina Walter, and Jiri Pavlíček explore leadership, legacy, and MedTech innovation from AI and MDR to building value beyond profit. A masterclass in resilience and impact.
Femtech Isn’t a Niche. It’s a Blind Spot. Why I’m Betting on Founders Who Refuse to Be Silenced.
Femtech isn’t a niche; it’s core healthcare. This article explores why rigorous, inclusive innovation in women’s health is overdue, underfunded, and strategically essential. Featuring YON E Health’s clinically validated approach to pH and BBT tracking.
Building the Central European Venture Engine: From Founders to Scalable Companies
Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer of Uniprisma about founder psychology, scaling discipline, and why the next wave of innovation will come from execution, not hype.
From Pain to Purpose: Scaling Femtech with Precision and Purpose
A powerful conversation with YON E Health founders on transforming trauma into innovation. Peter M. Kovacs explores how Femtech is closing clinical data gaps, redefining investment, and scaling inclusive health technology.
AI in Europe: Building Bridges Between Policy, Business, and Healthcare
AI in Europe requires both ethics and competitiveness. In this episode, Peter M. Kovacs, Pavlina Walter, and Jan Kavalírek explore AI regulation, EU bureaucracy, and the balance between trust, safety, and global competition.
Access to Patients - The Hardest Part of Clinical Research
Patient access is the biggest bottleneck in clinical trials. This article explores why recruitment is so difficult, how databases, referrals, and digital outreach help, and why solving this issue is critical to delivering life-changing treatments faster.
Who We Are: PMK Group and Our Mission in Biotech
PMK Group reduces biotech risk by combining capital with clinical expertise. Dr. Peter M. Kovacs explains how operational involvement lowers trial failures and accelerates medical innovation.
AI and Healthcare Innovation with Lukas Benzel, Pavlina Walterand Peter M. Kovacs
Prague podcast on AI and healthcare with Peter M. Kovacs, Pavlina Walter, and Lukas Benzel. From hospital adoption to prevention, clinical trials, EU strategy, and lessons from Singapore. Practical playbooks for investors, founders, and operators.
From Budapest to Singapore - A Life-Changing Decision
From Budapest to Singapore, Dr. Peter M. Kovacs shares his bold move to Asia, explains why Singapore became his global hub, and discusses its implications for healthcare, biotech, and investment.
Clinical Research Doesn’t Need More Money, It Needs Better Execution
Clinical research doesn’t need more funding, it needs better execution. Discover a proven operational model that accelerates milestones, improves data quality, and reduces capital waste by 30–50%, offering a strategic edge for institutional co-investors.